Improving Rare Disease Awareness: Paul Wuh-Liang Hwu, MD, PhD

Video

The professor from National Taiwan University Hospital discussed the importance of Rare Disease Day for raising awareness.

“The first step to work on in rare disorders is the diagnosis. In order to increase diagnoses, we need to increase awareness. In order to increase awareness, I think the best way is better education. So, we need to persuade authorities that this education is very important, and they should represent a certain percentage of their continuing education program to cover those rare disorders.”

Monday, February 28, is international Rare Disease Day. Rare diseases affect over 300 million people worldwide, with over 7000 diseases designated as rare.

Companies are developing gene and cell therapies for rare diseases such as Pompe disease and aromatic L-amino acid decarboxylase (AADC) deficiency, including PTC Therapeutics’ gene therapy PTC-AADC. Paul Wuh-Liang Hwu, MD, PhD, professor of pediatrics, National Taiwan University Hospital, serves as investigator on the PTC-AADC trials.

CGTLive spoke with Hwu about Rare Disease Day, rare disease awareness, and physician education. He also discussed the importance of patient advocacy and the improvements that still need to be made in these areas to advance both our understanding and management of rare diseases.

Related Videos
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.